New hope for lung cancer patients whose tumors outsmart current therapy
NCT ID NCT04606771
First seen Oct 31, 2025 · Last updated May 24, 2026 · Updated 27 times
Summary
This study tests whether adding savolitinib to the standard drug osimertinib can shrink tumors or slow cancer growth in people with a specific type of advanced lung cancer (EGFR mutation-positive and MET amplified) that has worsened despite osimertinib treatment. About 30 adults will be randomly assigned to receive either savolitinib plus osimertinib or savolitinib plus a placebo. The main goal is to see how many patients have their tumors shrink significantly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Duarte, California, 91010, United States
-
Research Site
Sacramento, California, 95817, United States
-
Research Site
Ciudad de Buenos Aires, C1120AAT, Argentina
-
Research Site
Delhi, 110085, India
-
Research Site
Mumbai, 400053, India
-
Research Site
Taichung, 402, Taiwan
-
Research Site
Taipei, 100, Taiwan
-
Research Site
Taipei, 11217, Taiwan
-
Research Site
Taipei, 235, Taiwan
-
Research Site
Taoyuan City, 333, Taiwan
-
Research Site
Bangkok, 10210, Thailand
-
Research Site
Bangkok, 10300, Thailand
-
Research Site
Bangkok, 10330, Thailand
-
Research Site
Bangkok, 10400, Thailand
-
Research Site
Bangkok, 10700, Thailand
-
Research Site
Hat Yai, 90110, Thailand
-
Research Site
Khon Kaen, 40002, Thailand
-
Research Site
Muang, 50200, Thailand
-
Research Site
Hanoi, 100000, Vietnam
-
Research Site
Hà Nội, 100000, Vietnam
-
Research Site
Ho Chi Minh City, 700000, Vietnam
Conditions
Explore the condition pages connected to this study.